Provided by Tiger Trade Technology Pte. Ltd.

Omeros

10.18
-0.4800-4.50%
Post-market: 10.480.3000+2.95%18:21 EDT
Volume:955.89K
Turnover:9.82M
Market Cap:721.77M
PE:-5.07
High:10.59
Open:10.50
Low:10.05
Close:10.66
52wk High:17.65
52wk Low:2.95
Shares:70.90M
Float Shares:64.55M
Volume Ratio:1.05
T/O Rate:1.48%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.0098
EPS(LYR):-2.6958
ROE:-576.33%
ROA:-32.41%
PB:-3.27
PE(LYR):-3.78

Loading ...

Analysts Are Neutral on Top Healthcare Stocks: Biohaven Ltd. (BHVN), Omeros (OMER)

TIPRANKS
·
Dec 25, 2025

BUZZ-U.S. STOCKS ON THE MOVE-Snowflake, Hecla Mining, Newmont

Reuters
·
Dec 25, 2025

Top Midday Gainers

MT Newswires Live
·
Dec 25, 2025

Omeros Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Dec 25, 2025

Omeros Shares Surge on FDA Approval For Yartemlea

Dow Jones
·
Dec 25, 2025

Dow Gains Over 100 Points; US Jobless Claims Decline

Benzinga
·
Dec 24, 2025

Omeros Shares Rise 81.7% After US FDA Approves Co's Drug to Treat Dangerous Transplant Complication

THOMSON REUTERS
·
Dec 24, 2025

BRIEF-FDA Approves Omeros’ YARTEMLEA

Reuters
·
Dec 24, 2025

US FDA approves Omeros' drug to treat dangerous transplant complication

Reuters
·
Dec 24, 2025

FDA Approves Omeros' YARTEMLEA for TA-TMA Treatment

Reuters
·
Dec 24, 2025

Omeros Corp - Plans U.S. Product Launch of Yartemlea in January 2026

THOMSON REUTERS
·
Dec 24, 2025

FDA Approves Omeros’ Yartemlea® – First and Only Therapy Indicated for Ta-Tma

THOMSON REUTERS
·
Dec 24, 2025

NASDAQ TRADE HALT HALT NEWS PENDING AT 06:36 AM

Reuters
·
Dec 24, 2025

Sector Update: Health Care Stocks Decline Late Afternoon

MT Newswires Live
·
Dec 02, 2025

Omeros Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Dec 02, 2025

Omeros Corp - Approves $100 Mln Share Repurchase Program - SEC Filing

THOMSON REUTERS
·
Dec 01, 2025

Omeros Corporation Prepays $67.1 Million Senior Secured Term Loan, Terminates Credit Agreement

Reuters
·
Dec 01, 2025

Omeros Corporation Announces Closing of Asset Purchase and License Agreement With Novo Nordisk for Omeros’ Clinical-Stage Masp-3 Inhibitor Zaltenibart (Oms906)

THOMSON REUTERS
·
Dec 01, 2025

Press Release: Omeros Corporation Announces Closing of Asset Purchase and License Agreement with Novo Nordisk for Omeros' Clinical-Stage MASP-3 Inhibitor Zaltenibart (OMS906)

Dow Jones
·
Dec 01, 2025

Omeros Corporation (NASDAQ:OMER): When Will It Breakeven?

Simply Wall St.
·
Nov 29, 2025